688192 迪哲医药
已收盘 04-03 15:00:00
资讯
新帖
简况
图解迪哲医药年报：第四季度单季净利润同比增长35.96%
证券之星 · 03-31
图解迪哲医药年报：第四季度单季净利润同比增长35.96%
迪哲医药（688192）披露舒沃哲一线治疗EGFR PACC或其他罕见突变非小细胞肺癌最新数据，3月30日股价下跌0.71%
证券之星 · 03-30
迪哲医药（688192）披露舒沃哲一线治疗EGFR PACC或其他罕见突变非小细胞肺癌最新数据，3月30日股价下跌0.71%
迪哲医药公布最新临床试验结果；安徽质子治疗费大幅降价
21世纪经济报道 · 03-23
迪哲医药公布最新临床试验结果；安徽质子治疗费大幅降价
迪哲医药(688192.SH)：舒沃哲®单药一线治疗EGFRexon20ins非小细胞肺癌国际多中心III期临床试验获阳性顶线结果
智通财经 · 03-22
迪哲医药(688192.SH)：舒沃哲®单药一线治疗EGFRexon20ins非小细胞肺癌国际多中心III期临床试验获阳性顶线结果
每周股票复盘：迪哲医药（688192）现溢价19.21%大宗交易
证券之星 · 03-22
每周股票复盘：迪哲医药（688192）现溢价19.21%大宗交易
3月19日迪哲医药现1笔溢价19.21%的大宗交易 合计成交333.42万元
证券之星 · 03-19
3月19日迪哲医药现1笔溢价19.21%的大宗交易 合计成交333.42万元
新股消息 | 迪哲医药(688192.SH)拟港股上市 中国证监会要求补充说明董事与高管相互之间存在的关联关系等
智通财经网 · 03-13
新股消息 | 迪哲医药(688192.SH)拟港股上市 中国证监会要求补充说明董事与高管相互之间存在的关联关系等
迪哲医药跌3% 2021年上市中信证券保荐2募资共39亿
中金财经 · 03-12
迪哲医药跌3% 2021年上市中信证券保荐2募资共39亿
每周股票复盘：迪哲医药（688192）提前归还10,336.33万元闲置募资
证券之星 · 03-08
每周股票复盘：迪哲医药（688192）提前归还10,336.33万元闲置募资
迪哲医药（688192）披露关于提前归还临时补充流动资金的闲置募集资金的公告，3月6日股价上涨4.53%
证券之星 · 03-06
迪哲医药（688192）披露关于提前归还临时补充流动资金的闲置募集资金的公告，3月6日股价上涨4.53%
股市必读：迪哲医药发布2025年度业绩快报，亏损7.633亿元
证券之星 · 03-02
股市必读：迪哲医药发布2025年度业绩快报，亏损7.633亿元
每周股票复盘：迪哲医药（688192）2025年营收增122.60%
证券之星 · 03-01
每周股票复盘：迪哲医药（688192）2025年营收增122.60%
迪哲医药（688192）披露2025年度业绩快报公告，2月27日股价上涨1.17%
证券之星 · 02-27
迪哲医药（688192）披露2025年度业绩快报公告，2月27日股价上涨1.17%
迪哲医药（688192）99.11万股限售股将于2月24日解禁，占总股本0.21%
证券之星 · 02-24
迪哲医药（688192）99.11万股限售股将于2月24日解禁，占总股本0.21%
去年预亏7.7亿元，迪哲医药冲刺港股IPO
21世纪经济报道 · 01-28
去年预亏7.7亿元，迪哲医药冲刺港股IPO
营收爬坡、烧钱依旧，迪哲医药急赴港股再融资
市场资讯 · 01-25
营收爬坡、烧钱依旧，迪哲医药急赴港股再融资
新股消息 | 迪哲医药(688192.SH)递表港交所
智通财经 · 01-24
新股消息 | 迪哲医药(688192.SH)递表港交所
迪哲医药（688192）披露关于变更公司英文名称、修订《公司章程》并办理工商变更登记的公告，1月21日股价下跌1.48%
证券之星 · 01-21
迪哲医药（688192）披露关于变更公司英文名称、修订《公司章程》并办理工商变更登记的公告，1月21日股价下跌1.48%
迪哲医药：预计2025年净利润亏损7.7亿元左右
证券之星 · 01-12
迪哲医药：预计2025年净利润亏损7.7亿元左右
每周股票复盘：迪哲医药（688192）拟发行H股赴港上市
证券之星 · 01-11
每周股票复盘：迪哲医药（688192）拟发行H股赴港上市
加载更多
公司概况
公司名称：
迪哲(江苏)医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-12-10
主营业务：
迪哲(江苏)医药股份有限公司的主营业务是专注于肿瘤、血液系统疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲。公司获第七批国家级专精特新“小巨人”企业认定。此外，公司首款源头创新产品舒沃哲的研发及产业化项目，荣获江苏省科技进步奖一等奖。
发行价格：
52.58
{"stockData":{"symbol":"688192","market":"SH","secType":"STK","nameCN":"迪哲医药","latestPrice":57.5,"timestamp":1775199600000,"preClose":58.57,"halted":0,"volume":4429227,"delay":0,"changeRate":-0.0183,"floatShares":461000000,"shares":465000000,"eps":-1.4682,"marketStatus":"已收盘","change":-1.07,"latestTime":"04-03 15:00:00","open":56.76,"high":58.19,"low":55.9,"amount":253000000,"amplitude":0.0391,"askPrice":57.56,"askSize":33,"bidPrice":57.5,"bidSize":121,"shortable":0,"etf":0,"ttmEps":-1.4682,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775525400000},"marketStatusCode":5,"adr":0,"adjPreClose":58.57,"symbolType":"stock_kcb","openAndCloseTimeList":[[1775179800000,1775187000000],[1775192400000,1775199600000]],"highLimit":64.43,"lowLimit":52.71,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":464633342,"isCdr":false,"pbRate":20.65,"roa":"--","roe":"--","epsLYR":-1.71,"committee":0.309417,"marketValue":26716000000,"turnoverRate":0.0096,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-04-08。","afterMarket":{"amount":0,"volume":0,"close":57.5,"buyVolume":0,"sellVolume":0,"time":1775201637560,"indexStatus":"已收盘 04-03 15:30:00","preClose":58.57},"floatMarketCap":26489000000},"requestUrl":"/m/hq/s/688192","defaultTab":"news","newsList":[{"id":"2623932334","title":"图解迪哲医药年报：第四季度单季净利润同比增长35.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623932334","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623932334?lang=zh_cn&edition=full","pubTime":"2026-03-31 02:01","pubTimestamp":1774893665,"startTime":"0","endTime":"0","summary":"证券之星消息，迪哲医药2025年年报显示，当年度公司主营收入8.01亿元，同比上升122.6%；归母净利润-7.64亿元，同比上升9.68%；扣非净利润-8.42亿元，同比上升6.38%；其中2025年第四季度，公司单季度主营收入2.15亿元，同比上升901.58%；单季度归母净利润-1.84亿元，同比上升35.96%；单季度扣非净利润-2.11亿元，同比上升29.55%；负债率56.85%，财务费用3019.1万元，毛利率95.73%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033100004829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623313166","title":"迪哲医药（688192）披露舒沃哲一线治疗EGFR PACC或其他罕见突变非小细胞肺癌最新数据，3月30日股价下跌0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623313166","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623313166?lang=zh_cn&edition=full","pubTime":"2026-03-30 17:29","pubTimestamp":1774862990,"startTime":"0","endTime":"0","summary":"截至2026年3月30日收盘，迪哲医药报收于55.6元，较前一交易日下跌0.71%，最新总市值为258.34亿元。近日，迪哲医药发布自愿披露公告，舒沃哲在2026年欧洲肺癌大会上发布一线治疗EGFR PACC或其他罕见突变非小细胞肺癌的最新数据。15例基线脑转移患者中有11例肿瘤缓解，6例确认部分缓解。中位缓解持续时间未达到，81.3%患者仍在治疗，6个月持续缓解率预估87.5%。9个月无进展生存率预估83.9%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026033000024038.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621740280","title":"迪哲医药公布最新临床试验结果；安徽质子治疗费大幅降价","url":"https://stock-news.laohu8.com/highlight/detail?id=2621740280","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621740280?lang=zh_cn&edition=full","pubTime":"2026-03-23 09:07","pubTimestamp":1774228034,"startTime":"0","endTime":"0","summary":"政策动向商务部：在部分有条件的地区探索建设国际医疗旅游集聚区3月20日，商务部发布《关于促进旅行服务出口扩大入境消费的政策措施》。在部分有条件的地区探索建设国际医疗旅游集聚区，面向国际患者提供高端体检、整形美容、康复护理等服务。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603233679899856.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603233679899856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621719302","title":"迪哲医药(688192.SH)：舒沃哲®单药一线治疗EGFRexon20ins非小细胞肺癌国际多中心III期临床试验获阳性顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2621719302","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621719302?lang=zh_cn&edition=full","pubTime":"2026-03-22 15:43","pubTimestamp":1774165425,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)公告，公司自主研发的产品舒沃哲®(ZEGFROVY®，通用名：舒沃替尼片)单药一线治疗表皮生长因子受体(EGFR)20号外显子插入突变(exon20ins)晚期非小细胞肺癌(NSCLC)的国际多中心III期临床研究“悟空28”(WU-KONG28)达到主要研究终点、取得阳性顶线结果，是全球首个且唯一在国际多中心随机对照III期临床研究中，针对EGFRexon20ins NSCLC一线治疗取得阳性结果的口服靶向药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK4134","688192","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621088799","title":"每周股票复盘：迪哲医药（688192）现溢价19.21%大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2621088799","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621088799?lang=zh_cn&edition=full","pubTime":"2026-03-22 03:14","pubTimestamp":1774120450,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，迪哲医药报收于48.64元，较上周的48.23元上涨0.85%。本周，迪哲医药3月17日盘中最高价报52.33元。3月16日盘中最低价报47.6元。迪哲医药当前最新总市值226.0亿元，在化学制药板块市值排名18/150，在两市A股市值排名901/5190。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200001229.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620245866","title":"3月19日迪哲医药现1笔溢价19.21%的大宗交易 合计成交333.42万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620245866","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620245866?lang=zh_cn&edition=full","pubTime":"2026-03-19 17:20","pubTimestamp":1773912047,"startTime":"0","endTime":"0","summary":"证券之星消息，3月19日迪哲医药发生大宗交易，交易数据如下：大宗交易成交价格59.19元，相对当日收盘价溢价19.21%，成交5.63万股，成交金额333.42万元，买方营业部为方正证券股份有限公司重庆金开大道证券营业部，卖方营业部为西南证券股份有限公司重庆第四分公司。近三个月该股共发生1笔大宗交易，合计成交563.0手，溢价成交1笔。截至2026年3月19日收盘，迪哲医药报收于49.65元，下跌2.11%，换手率0.37%，成交量1.68万手，成交额8444.1万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900028128.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619194222","title":"新股消息 | 迪哲医药(688192.SH)拟港股上市 中国证监会要求补充说明董事与高管相互之间存在的关联关系等","url":"https://stock-news.laohu8.com/highlight/detail?id=2619194222","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619194222?lang=zh_cn&edition=full","pubTime":"2026-03-13 19:42","pubTimestamp":1773402144,"startTime":"0","endTime":"0","summary":"中国证监会发布《境外发行上市备案补充材料要求(2026年3月3日—2026年3月13日)》。中国证监会国际司共对8家企业出具补充材料要求，其中，要求迪哲医药补充说明董事、高级管理人员相互之间存在的关联关系情况等事项。","market":"us","thumbnail":"https://img.zhitongcaijing.com/image/20260313/20260313194246_25749.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260313/20260313194246_25749.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4588","688192","BK4585","BK0239","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618318432","title":"迪哲医药跌3% 2021年上市中信证券保荐2募资共39亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2618318432","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618318432?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:33","pubTimestamp":1773304391,"startTime":"0","endTime":"0","summary":"中国经济网北京3月12日讯 迪哲医药 今日收报49.19元，跌幅3.00%，总市值228.55亿元。该股目前处于破发状态。 迪哲医药于2021年12月10日在上交所科创板上市，发行股票4000.01万股，发行价格为52.58元/股。 迪哲医药首次公开发行股票募集资金总额为21.03亿元，扣除发行费用后募集资金净额为19.87亿元。迪哲医药最终募集资金净额比原计划多2.03亿元。 迪哲医药2次募资合计募集资金38.99亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260312/32063314.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0196","LU1997244956.HKD","BK0183","BK0276","LU1997245094.SGD","LU2495084118.USD","LU1328615791.USD","LU1255011170.USD","LU1997245177.USD","BK0239","06030","BK1147","LU0405327494.USD","LU1064131003.USD","BK1521","600030","LU2289578879.USD","BK0188","BK0028","688192","LU1655091616.SGD","LU1794554557.SGD","LU1720050803.USD","LU0405327148.USD","LU2148510915.USD","LU1064130708.USD","BK0012","BK1564","BK1516"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617668742","title":"每周股票复盘：迪哲医药（688192）提前归还10,336.33万元闲置募资","url":"https://stock-news.laohu8.com/highlight/detail?id=2617668742","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617668742?lang=zh_cn&edition=full","pubTime":"2026-03-08 02:22","pubTimestamp":1772907732,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，迪哲医药报收于50.75元，较上周的50.9元下跌0.29%。本周，迪哲医药3月6日盘中最高价报51.57元。本周关注点公司公告汇总：迪哲医药已提前全额归还临时补充流动资金的10,336.33万元闲置募集资金。公司实际使用10,336.33万元，截至2026年3月6日已将该款项全部提前归还至募集资金专用账户，使用期限未超过董事会批准期限，并已通知保荐机构和保荐代表人。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800000708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617636553","title":"迪哲医药（688192）披露关于提前归还临时补充流动资金的闲置募集资金的公告，3月6日股价上涨4.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2617636553","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617636553?lang=zh_cn&edition=full","pubTime":"2026-03-06 22:36","pubTimestamp":1772807780,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，迪哲医药报收于50.75元，较前一交易日上涨4.53%，最新总市值为235.8亿元。该股当日开盘48.55元，最高51.57元，最低48.37元，成交额达1.5亿元，换手率为0.64%。近日，迪哲（江苏）医药股份有限公司发布《关于提前归还临时补充流动资金的闲置募集资金的公告》。公司实际使用10,336.33万元，截至2026年3月6日已将该款项全部提前归还至募集资金专用账户，使用期限未超过董事会批准期限，并已通知保荐机构和保荐代表人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600040448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616875004","title":"股市必读：迪哲医药发布2025年度业绩快报，亏损7.633亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2616875004","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616875004?lang=zh_cn&edition=full","pubTime":"2026-03-02 02:36","pubTimestamp":1772390173,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，迪哲医药报收于50.9元，上涨1.17%，换手率0.3%，成交量1.4万手，成交额7101.84万元。来自业绩披露要点：迪哲医药预计2025年归属净利润亏损7.633亿元，同比减亏9.77%。来自公司公告汇总：迪哲医药发布2025年度业绩快报，营业总收入同比增长122.60%，两产品纳入国家医保推动销售放量。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030200001177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616843066","title":"每周股票复盘：迪哲医药（688192）2025年营收增122.60%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616843066","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616843066?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:26","pubTimestamp":1772303172,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，迪哲医药报收于50.9元，较上周的53.85元下跌5.48%。本周，迪哲医药2月24日盘中最高价报54.49元。本周关注点来自业绩披露要点：迪哲医药2025年营业总收入80,113.56万元，同比增长122.60%。来自公司公告汇总：迪哲医药完成定向增发，募集资金净额17.73亿元。公司公告汇总迪哲医药发布2025年度业绩快报，营业总收入80,113.56万元，同比增长122.60%；归属于母公司所有者的净利润为-76,331.12万元，亏损同比减少8,264.51万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614857527","title":"迪哲医药（688192）披露2025年度业绩快报公告，2月27日股价上涨1.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614857527","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614857527?lang=zh_cn&edition=full","pubTime":"2026-02-27 23:00","pubTimestamp":1772204446,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，迪哲医药报收于50.9元，较前一交易日上涨1.17%，最新总市值为236.5亿元。该股当日开盘50.31元，最高51.03元，最低49.56元，成交额达7101.84万元，换手率为0.3%。近日，迪哲医药发布2025年度业绩快报，营业总收入80,113.56万元，同比增长122.60%；归属于母公司所有者的净利润为-76,331.12万元，亏损同比减少8,264.51万元。报告期内完成定向增发，募集资金净额17.73亿元，总资产和净资产显著增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700042920.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613567167","title":"迪哲医药（688192）99.11万股限售股将于2月24日解禁，占总股本0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613567167","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613567167?lang=zh_cn&edition=full","pubTime":"2026-02-24 08:02","pubTimestamp":1771891349,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，迪哲医药于2月24日将有99.11万股限售股份解禁，为公司股权激励期权行权，占公司总股本0.21%。最近一年内，该股累计解禁2.68亿股，占总股本的57.63%。本次解禁后，公司还有395.18万股限售股份，占总股本0.85%。迪哲医药主营业务：专注于恶性肿瘤、免疫性疾病领域创新疗法的研究、开发和商业化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400010438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606942777","title":"去年预亏7.7亿元，迪哲医药冲刺港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2606942777","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606942777?lang=zh_cn&edition=full","pubTime":"2026-01-28 17:56","pubTimestamp":1769594160,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者 韩利明继益方生物（688382.SH）、泽璟制药（688266.SH）、信立泰（002294.SZ）、悦康药业（688658.SH）等本土药企在2025年底密集披露港股上市计划后，迪哲医药（688192. ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20260128/c674373712.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260128/c674373712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606726994","title":"营收爬坡、烧钱依旧，迪哲医药急赴港股再融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2606726994","media":"市场资讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606726994?lang=zh_cn&edition=full","pubTime":"2026-01-25 18:39","pubTimestamp":1769337540,"startTime":"0","endTime":"0","summary":" 产品放量带来的减亏，并未改变资金的紧迫局面，迪哲医药将目光投向港交所。近日，迪哲医药正式向港交所递交上市申请，谋求港股上市。面对仍在持续的研发投入和常年亏损带来的历史缺口，迪哲医药的资金压力依旧高悬。此前A股募资已近枯竭，为维持多条核心管线的同步推进、避免在商业化冲刺前“失血”，赴港上市已成为支撑迪哲医药存活至盈利前的关键一役。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-01-25/doc-inhipmct8978957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["162717","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605872235","title":"新股消息 | 迪哲医药(688192.SH)递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2605872235","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605872235?lang=zh_cn&edition=full","pubTime":"2026-01-24 17:39","pubTimestamp":1769247557,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所1月23日披露，迪哲(江苏)医药股份有限公司(简称：迪哲医药(688192.SH))向港交所主板递交上市申请书，高盛和华泰国际为其联席保荐人。据招股书，迪哲医药是一家处于商业化阶段的生物制药公司，公司的核心治疗领域是肿瘤及血液系统疾病。公司的上市产品舒沃哲®是全球范围内唯一获批用于治疗EGFR 20号外显子插入突变型肺癌的小分子表皮生长因子受体酪氨酸激酶抑制剂。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396984.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688192","HEXmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605483414","title":"迪哲医药（688192）披露关于变更公司英文名称、修订《公司章程》并办理工商变更登记的公告，1月21日股价下跌1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605483414","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605483414?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:30","pubTimestamp":1769005838,"startTime":"0","endTime":"0","summary":"截至2026年1月21日收盘，迪哲医药报收于61.79元，较前一交易日下跌1.48%，最新总市值为286.72亿元。近日，迪哲（江苏）医药股份有限公司召开第二届董事会第十九次会议，审议通过了《关于变更公司英文名称、修订〈公司章程〉并办理工商变更登记的议案》。董事会已授权公司管理层办理相关工商变更、登记及备案事宜。本次修订仅涉及公司英文名称变更，其他条款保持不变，最终以市场监督管理部门登记备案为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100041104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602515147","title":"迪哲医药：预计2025年净利润亏损7.7亿元左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2602515147","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602515147?lang=zh_cn&edition=full","pubTime":"2026-01-12 18:20","pubTimestamp":1768213246,"startTime":"0","endTime":"0","summary":"迪哲医药(688192.SH)公告称，迪哲医药发布2025年度业绩预告，预计归属于母公司所有者的净亏损7.7亿元左右，较上年同期减少亏损约7,596万元。报告期内，公司两款获批产品舒沃哲和高瑞哲纳入国家医保药品目录，推动产品销售收入增长至约8亿元，同比增长122.28%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200026699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602535300","title":"每周股票复盘：迪哲医药（688192）拟发行H股赴港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2602535300","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602535300?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:36","pubTimestamp":1768070169,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，迪哲医药报收于66.79元，较上周的57.6元上涨15.95%。本周，迪哲医药1月9日盘中最高价报67.08元。1月5日盘中最低价报56.52元。迪哲医药当前最新总市值308.03亿元，在化学制药板块市值排名14/150，在两市A股市值排名681/5182。所有议案均获通过，无被否决议案。北京市中伦律师事务所对本次股东会进行见证并出具法律意见书，确认会议的召集、召开程序、出席人员资格、表决程序及表决结果合法有效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1775293183387,"stockEarnings":[{"period":"1week","weight":0.0268},{"period":"1month","weight":0.2082},{"period":"3month","weight":-0.0017},{"period":"6month","weight":-0.2061},{"period":"1year","weight":0.1051},{"period":"ytd","weight":-0.0017}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":-0.0496},{"period":"3month","weight":-0.0224},{"period":"6month","weight":-0.0007},{"period":"1year","weight":0.161},{"period":"ytd","weight":-0.0224}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迪哲(江苏)医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"10012人(较上一季度增加8.37%)","perCapita":"46012股","listingDate":"2021-12-10","address":"江苏省无锡市新吴区和风路26号汇融商务广场C栋404、405、416室","registeredCapital":"46463万元","survey":" 迪哲(江苏)医药股份有限公司的主营业务是专注于肿瘤、血液系统疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲。公司获第七批国家级专精特新“小巨人”企业认定。此外，公司首款源头创新产品舒沃哲的研发及产业化项目，荣获江苏省科技进步奖一等奖。","listedPrice":52.58},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪哲医药,688192,迪哲医药股票,迪哲医药股票老虎,迪哲医药股票老虎国际,迪哲医药行情,迪哲医药股票行情,迪哲医药股价,迪哲医药股市,迪哲医药股票价格,迪哲医药股票交易,迪哲医药股票购买,迪哲医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}